• Je něco špatně v tomto záznamu ?

Educate, not kill: treating cancer without triggering its defenses

A. Škarková, M. Bizzarri, R. Janoštiak, J. Mašek, D. Rosel, J. Brábek

. 2024 ; 30 (7) : 673-685. [pub] 20240423

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019924

Traditionally, anticancer therapies focus on restraining uncontrolled proliferation. However, these cytotoxic therapies expose cancer cells to direct killing, instigating the process of natural selection favoring survival of resistant cells that become the foundation for tumor progression and therapy failure. Recognizing this phenomenon has prompted the development of alternative therapeutic strategies. Here we propose strategies targeting cancer hallmarks beyond proliferation, aiming at re-educating cancer cells towards a less malignant phenotype. These strategies include controlling cell dormancy, transdifferentiation therapy, normalizing the cancer microenvironment, and using migrastatic therapy. Adaptive resistance to these educative strategies does not confer a direct proliferative advantage to resistant cells, as non-resistant cells are not subject to eradication, thereby delaying or preventing the development of therapy-resistant tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019924
003      
CZ-PrNML
005      
20241024110841.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.molmed.2024.04.003 $2 doi
035    __
$a (PubMed)38658206
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Škarková, Aneta $u Department of Cell Biology, BIOCEV, Faculty of Science, Charles University, Vestec, Czech Republic
245    10
$a Educate, not kill: treating cancer without triggering its defenses / $c A. Škarková, M. Bizzarri, R. Janoštiak, J. Mašek, D. Rosel, J. Brábek
520    9_
$a Traditionally, anticancer therapies focus on restraining uncontrolled proliferation. However, these cytotoxic therapies expose cancer cells to direct killing, instigating the process of natural selection favoring survival of resistant cells that become the foundation for tumor progression and therapy failure. Recognizing this phenomenon has prompted the development of alternative therapeutic strategies. Here we propose strategies targeting cancer hallmarks beyond proliferation, aiming at re-educating cancer cells towards a less malignant phenotype. These strategies include controlling cell dormancy, transdifferentiation therapy, normalizing the cancer microenvironment, and using migrastatic therapy. Adaptive resistance to these educative strategies does not confer a direct proliferative advantage to resistant cells, as non-resistant cells are not subject to eradication, thereby delaying or preventing the development of therapy-resistant tumors.
650    _2
$a lidé $7 D006801
650    12
$a nádory $x terapie $7 D009369
650    12
$a nádorové mikroprostředí $7 D059016
650    _2
$a zvířata $7 D000818
650    _2
$a chemorezistence $7 D019008
650    _2
$a protinádorové látky $x terapeutické užití $x farmakologie $7 D000970
650    _2
$a proliferace buněk $7 D049109
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bizzarri, Mariano $u System Biology Group Laboratory, Sapienza University, Rome, Italy
700    1_
$a Janoštiak, Radoslav $u First Faculty of Medicine, BIOCEV, Charles University, Vestec, Czech Republic
700    1_
$a Mašek, Jan $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Rosel, Daniel $u Department of Cell Biology, BIOCEV, Faculty of Science, Charles University, Vestec, Czech Republic. Electronic address: rosel@natur.cuni.cz
700    1_
$a Brábek, Jan $u Department of Cell Biology, BIOCEV, Faculty of Science, Charles University, Vestec, Czech Republic. Electronic address: brabek@natur.cuni.cz
773    0_
$w MED00006668 $t Trends in molecular medicine $x 1471-499X $g Roč. 30, č. 7 (2024), s. 673-685
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38658206 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110835 $b ABA008
999    __
$a ok $b bmc $g 2202253 $s 1231897
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 30 $c 7 $d 673-685 $e 20240423 $i 1471-499X $m Trends in molecular medicine $n Trends Mol Med $x MED00006668
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace